None listed
Conditions
Brief summary
A randomized controlled study aimed to evaluate the effectiveness of myofascial release, stretching, and isotonic exercises post-mesenchymal stem cell therapy (MSCs-BM) for the treatment of chronic low back discogenic pain due to severe lumbar spinal degeneration with involvement of multiple structures.
Interventions
"In-clinic" physical therapy interventions, including: Mode of delivery: one-to-one Setting: Clinic of Regenerative medicine, Lahore, Pakistan Adherence: Call the patient one day before and ask for a session the next day. Attendance will be marked on the online Medical Report (MR portal). 1. Stretching: lumbar extensors, hamstrings, calf muscles, and nerve glides, 7 repetitions each for 30 seconds. 2. Isotonic exercises: bent knee sit-ups, single knee-to-chest, william flexion, cat-camel exercise, trunk rotation stretch, glute bridge: 7 repetitions each with slow to medium speed 3. Myofascial Release: Direct myofascial release technique is used, which involves applying sustained pressure to the restricted fascia, aiming to elongate and soften it. The practitioner uses their hands to sink into the tissue and hold the pressure until a release is felt, often described as a softening or melting sensation. This protocol will be continued for one month, 5 days a week, immediately after a one-time bone marrow concentrate injection into spinal structures (i.e., discs, facets, spinal nerves, and sacroiliac joints). The physical therapy will be provided by consultant physical therapists having a minimum of 7 years of experience after the permission of the pain medicine doctor who performs stem cell therapy. The study will be a double-blinded, randomized controlled trial. Consent will be signed from the participant before random assignment in groups. Confidentiality will be maintained throughout the process.
Sponsors
Study design
Eligibility
Inclusion criteria
Patients having recent mesenchymal stem cell therapy for severe low back discogenic pain.
Exclusion criteria
Patients with an abnormal neurologic status, including cauda equina syndrome, immunosuppressed individuals with chronic infections or coagulopathy, and severe psychiatric disorders will be excluded. Patients with active cancer; bone marrow disorders; or having therapy of immunosuppressive drugs will also be excluded.